New research reveals distinct molecular subtypes of childhood type 1 diabetes linked to age at diagnosis

A groundbreaking study demonstrates that children with newly diagnosed type 1 diabetes exhibit diverse biological signatures based on age at onset, suggesting the need for age-specific diagnostic and treatment approaches.

Type 1 diabetes is increasingly being viewed as more than a single disease, and a new study in Signal Transduction and Targeted Therapy adds to that picture by showing that the biology of newly diagnosed children differs by age at onset. In the paper, researchers analysed gut microbiome, serum metabolites, serum lipids and peripheral blood immune transcripts from 108 paediatric patients with new-onset type 1 diabetes, alongside 56 healthy controls, and divided the patients into early-onset, intermediate-onset and late-onset groups based on age at diagnosis. The authors say the different age bands carried distinct molecular signatures, suggesting that age at onset may help define biologically meaningful subtypes rather than simply marking when the disease was detected. (nature.com)

The strongest microbial signal in the youngest children was the genus Acetatifactor, while the middle and older onset groups were more strongly associated with Firmicutes A and the family Bacteroidaceae, respectively, according to the study. Metabolic patterns also diverged: pipecolic acid stood out in early-onset disease, testosterone in the intermediate group and N-acetylhomocitrulline in the late-onset group. Lipid profiling followed the same age-linked pattern, with group-specific shifts in LPA(16:1) and triglycerides. The authors also reported that B-cell proportions were highest in the youngest children and lowest in the oldest group, with the youngest patients showing immune pathways linked to inflammation and the oldest showing more metabolism-related signatures. (nature.com)

One of the more notable findings was a proposed link between the microbial species Dialister invisus and B-cell proliferation, mediated through the fatty acid docosapentaenoic acid, which the authors suggest could help explain some of the biology of early-onset type 1 diabetes. That interpretation fits with a growing body of research arguing that age at diagnosis may map onto different immune and metabolic pathways in the disease. A 2025 review in Therapeutic Advances in Endocrinology and Metabolism similarly argued that circulating microRNAs could help identify patient subgroups and guide future disease-modifying treatment strategies, reinforcing the idea that biomarker-led stratification may become important in type 1 diabetes care. (nature.com)